Physician profile
Faiza Ferdousy
NPI 1366853921
$2,879.66
in general payments reported to CMS, 2019-2025
16 companies · $302 in 2025
The $302 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $23.07 · 2021: $368 · 2022: $746 · 2023: $671 · 2024: $769 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,742.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $538.74 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Janssen Pharmaceuticals, INC | $496.42 | 2020-2024 | Xarelto |
| Pfizer INC. | $332.05 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $330.48 | 2021-2025 | Ultomiris |
| Gilead Sciences, INC. | $293.09 | 2021-2025 | Veklury |
| Novartis Pharmaceuticals Corporation | $275.65 | 2021-2024 | |
| Abbvie INC. | $151.32 | 2024-2025 | |
| Livanova USA, INC. | $130.35 | 2023 | Tandemlife |
| E.R. Squibb & Sons, L.L.C. | $93.68 | 2021-2025 | Eliquis |
| Melinta Therapeutics, LLC | $61.75 | 2022-2025 | Rezzayo, Orbactiv, Kimyrsa |
| Astrazeneca Pharmaceuticals LP | $57.78 | 2022-2023 | Lokelma |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $39.86 | 2024 | Lifevest |
| Boston Scientific Corporation | $22.98 | 2021 | |
| Biomerieux INC | $22.21 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.74 | 2023 | Jardiance |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.56 | 2023 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faiza Ferdousy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.